BIOMAT Database Logo BIOMAT Database Logo

[Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a]. 1989

A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Abteilung Hämatologie, Departement Innere Medizin, Kantonsspital Basel.

In a prospective open study 16 consecutive patients with a myeloproliferative syndrome and thrombocytosis were treated with interferon (IFN) alpha-2a. 4 patients had polycythemia vera, 4 essential thrombocythemia, 3 myeloid metaplasia and 5 chronic granulocytic leukemia. Platelet counts decreased in all treated patients within 2 to 12 weeks from a median value of 1010 x 10(9)/l to 350 x 10(9)/l. No primary or secondary resistance was observed. The initial dose of IFN was 9 m U per day. After correction of the thrombocytosis, it was progressively reduced to a minimum dose of 3 m U per week. Despite the good platelet response to IFN, leukocytosis persisted in 3 patients and polycythemia in a further 3. Side effects and poor compliance required discontinuation of therapy in 6 patients. Special attention is focused on the follow-up in 6 patients who have been treated for more than 15 months.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009196 Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
May 1989, The American journal of medicine,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
[Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis].
January 1993, Duodecim; laaketieteellinen aikakauskirja,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
March 1989, Lancet (London, England),
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
[Interferon-alpha in the treatment of myeloproliferative syndromes].
November 1994, Recenti progressi in medicina,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Human leucocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alfa 2a.
January 1994, European journal of cancer (Oxford, England : 1990),
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes.
December 2007, Leukemia & lymphoma,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
Recombinant alpha-2a interferon in HIV-associated myelodysplasia.
January 1988, Haematologica,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
January 1985, Acta medica Austriaca,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
[Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
November 1993, Medicina clinica,
A Tichelli, and A Gratwohl, and F Delacrétaz, and H Dazzi, and C Stebler, and M Wernli, and E E Holdener, and C Nissen, and B Speck
[Multiple mononeuropathy during recombinant interferon-alpha 2a therapy for chronic hepatitis C].
September 1992, Rinsho shinkeigaku = Clinical neurology,
Copied contents to your clipboard!